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Abstract
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Rheumatoid arthritis (RA) is a systemic inflammatory disorder that manifests
predominantly in the synovial joint, where it causes a chronic inflammatory process,
leading to early osteoarticular destructions. These destructions are progressive and
irreversible, generating a significant functional deficiency. During the last years, the
diagnostic approach of RA has focused on early arthritis. Early arthritis can develop into
established RA or another established arthropathy, like systemic lupus erythematosus or
psoriatic arthritis. It can have a spontaneous resolution or may remain undifferentiated
for indefinite periods of time.
The management of early arthritis has changed considerably in the past few years,
under the influence of new concepts of diagnosis and new effective therapies. The
treatment goal of early arthritis should now be the clinical remission and prevention of
joint destruction. Methotrexate is the first line of therapy, used to treat early arthralgia
and to reverse or limit impending exacerbation to RA. Biological treatment is used as a
second line therapy in patients with severe disease who do not respond or have a
contraindication to disease-modifying antirheumatic drugs (DMARDs). Patients with
early arthritis should usually be identified and directed to rheumatologists to confirm the
presence of arthritis, and to establish the correct diagnosis plus to initiate the proper
treatment strategies.
 early arthritis, rheumatoid arthritis, DMARDs, anticarbamilated protein antibodies.
✓ Patients with early arthritis should be referred to the rheumatologist, to be able to establish

a fast diagnosis and prompt therapy.
✓ The management of early arthritis should include not only drug treatment but also specific
medical education.
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Introduction
Rheumatoid arthritis (RA) is a systemic
inflammatory disorder that manifests predominantly in
the synovial joint, where it causes a chronic
inflammatory process, leading to osteoarticular
destructions. These destructions occur early and are
progressive and irreversible, generating a significant
functional deficiency. RA is frequently accompanied by
significant and varied systemic manifestations and could
reduce life expectancy due to several complications.
RA is the most common inflammatory rheumatic
illness. The articular and systemic consequences have a
significant impact on patients’ quality of life and
prognosis, but also on the healthcare systems. The
disease has considerable heterogeneity and can have
different forms: mild, non-erosive, sometimes with
spontaneous remission, or severe, rapidly progressive
forms, with significant and irreversible osteoarticular
destructions.
For a better prognosis of patients with RA,
establishing an earlier diagnosis and initiating treatment
is critical. In clinical practice, diagnosis of early arthritis
has become an important step. During the last years, the
diagnostic approach of RA is focused on early arthritis.
Inflammatory arthritis is one of the most common
pathological findings in clinical rheumatology.
Identifying the main disease can be very difficult,
especially in an early stage. In clinical practice, an early
inflammatory arthritis is often undifferentiated (1).
Early arthritis can often lead to established RA or other
arthropathies, such as systemic lupus erythematosus or
psoriatic arthritis.
Most of the symptoms in early arthritis remain
undifferentiated for indefinite periods of time. For a
better evaluation of the diagnosis of arthritis,
recognizing the inflammatory arthritis is necessary. The
next step is to search for a definite diagnosis and to
estimate the risk of developing persistent arthritis. An
optimal therapeutic strategy is essential (2, 3). Although
the prognosis of early arthritis is still difficult to assess,
a combination of clinical, laboratory, and radiological
findings may help to predict patients’ outcomes.

Discussions
Etiology
Numerous factors influence the onset of RA, the
majority being common with those involved in the
appearance of early arthritis. The exact cause of the RA
is unknown; it is considered a disease with multifactorial
complex determinism (4). It can have multiple risk
factors involving the host organism (e.g. genetic,

hormonal factors), environmental factors (smoking,
infections - Porphyromonas gingivalis, Ebstein Barr
virus, Mycoplasma pneumoniae), obesity, or socioeconomic status (5).
The evolutive phases of rheumatoid arthritis are
influenced by the presence of the risk factors: genetics
(HLA-DRB1, PTPN22, STAT4, PAD14), smoking or
bacteria like Porfiromonas gingivalis or Porfiromonas
copri (6).
These factors can precede the pre-clinical
rheumatoid arthritis phase (no symptoms), which
involves the systemic autoimmunity, with high levels of
rheumatoid factor, proinflammatory cytokines, high
sensitive C-reactive protein (CRP), and the positivity of
anti-citrullinated protein antibodies (ACPA) and antiprotein carbamylated antibodies (7).
Clinical manifestations
The early rheumatoid arthritis phase involves
nonspecific signs and symptoms, including articular
ones. The definite rheumatoid arthritis phase fulfills the
classification criteria, with systematic and articular
manifestations, high inflammatory markers such as Creactive protein (CRP) or erythrocyte sedimentation rate
(ESR), high rheumatoid factor, and positive anticitrullinated protein antibodies (ACPA) (8).
The diagnosis is based on the European League
Against Rheumatism (EULAR) defined characteristics,
patients with arthralgia being at risk for RA (9). These
parameters are used in patients with arthralgia without
clinical arthritis and without other diagnosis or other
explanation for the arthralgia. The diagnosis of RA
involves a history of joint symptoms with recent onset
(duration less than 1 year) (10); symptoms localized in
metacarpo-phalangeal joints; duration of morning
stiffness more than 60 minutes; most severe symptoms
present more in the early morning than the rest of the
day; presence of a first degree relative with RA; first
movement difficulties; and positive squeeze test of
metacarpophalangeal joints (11).
The undefined arthritis is approached differently by
two important rheumatology groups’ associations: the
Norfolk group defines it as two or more swollen joints,
for no less than two weeks, and the Leiden group sees it
as one or more swollen joints, diagnosed by a
rheumatologist, that have no other cause (12, 13).
Regarding the symptoms, there is a series of
nonspecific symptoms, like fatigue, undefined illness,
nonspecific muscular pain, mood disorders, or sub fever.
The articular symptoms include stiffness with variable
duration, non-characteristic to inflammatory pain,
nonspecific joint pain, symptoms of palindromic
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rheumatism and dysfunctional symptoms that can affect
the daily activities (14).
The connective-diseases screening questionnaire
and the rheumatoid arthritis questionnaire have high
specificity and sensibility. In a retrospective metaanalysis that included studies published between 19402012, using as inclusion criteria the symptoms of RA at
the onset of the disease, the authors have found that the
most frequent symptoms were joint swelling, local pain
and sensitivity, joint fatigue, fatigability, and asthenia,
all symptoms having an emotional impact (15).
Paraclinical diagnosis
Paraclinical diagnosis is based on laboratory tests
and imaging characteristics. Although there are no
specific biological markers or certain imaging tests for
early arthritis, because studies are still ongoing, most of
them are common for RA and early arthritis. The same
meta-analysis cited previously found positivity of anticitrullinated protein antibodies (ACPA) before
rheumatoid factor (FR) titers increased at a shorter
interval before diagnosis, a positive titer of anticitrullinated protein antibodies (ACPA), alpha tumor
necrosis factor (TNF alpha), interleukins 1,2 and 15 (IL
1, IL2, IL 15), and gamma interferon (15).
A brief report showed the presence of
anticarbamilated protein antibodies (anti-CarP) and their
role in predicting the development of RA (16). These are
relatively new antibodies, studies showing that 16% of
patients with RA have anti-CarP IgG even in the absence
of anti-citrullinated protein antibodies (ACPA). They
are associated with a severe destructive disease at the
articular level; they can be detected up to 4 years prior
to RA (16).
The anti-ribonucleoprotein A2/ anti RA22 nuclear
heterologous antibodies are present in 20-30% of
patients diagnosed with AR, but also in systemic lupus
erythematosus (SLE) or juvenile idiopathic arthritis
(JIA) (17). The epitope recognition is different in RA
patients, the specificity for RA is approximately 90%; it
is not associated with radiological progression. Serum
level equals the disease activity, with the tendency to
normalize during remission.
Imaging in early arthritis
Imaging has a very important role in the diagnosis
of RA. However, in early arthritis, imaging may not be
as useful as the clinical examination, due to the features
that tend to appear late, especially at ultrasonography.
Imaging is important in order to confirm the further
installation of RA.
Ultrasonography (US): A study combining routine
assessment and power Doppler ultrasonography was

performed in order to predict the progression to RA from
early-onset undifferentiated arthritis (18). The study
involved 149 patients with undifferentiated arthritis,
with early onset <16 weeks. The examined joints were
radiocarpal, metacarpophalangeal joints 2-5, and
interphalangeal joints 2-5 bilateral. The results showed
that the power Doppler signal present at more than 3
joints increases the probability of progression to AR to
41% and the positivity of anti-citrullinated protein
antibodies (ACPA) or rheumatoid factor increases the
probability to 65% (19).
Magnetic resonance imaging (MRI): In early
arthritis, we can use RAMRIS (Rheumatoid Arthritis
MRI Score) to observe the synovitis, erosion and bone
edema. Synovitis of interphalangeal joints is an
independent predictor for RA, with high relative risk.
Bone edema of metacarpo-phalangeal and radiocarpal
could be independent predictors (20).
Treatment of early arthritis
The management of an early arthritis has changed
substantially in the past few years as the result of new
concepts proposed for diagnosis and new effective
therapies. The treatment goal of such early arthritis
should now be represented by clinical remission and
prevention of joint destruction. The 2016 update of the
European League Against Rheumatism (EULAR)
recommendations for the management of early arthritis
(March 2017) includes 3 general principles and 12
recommendations (21).
Principles:
• The first principle indicates that the decisions taken
in the management of the disease should be based on the
relationship between patients and rheumatologist.
• The second principle highly recommends that
rheumatologists be the first specialists to examine the
patient with early arthritis.
• The third principle highlights the steps to the
definitive diagnosis of early arthritis that should be
made only after a full history and clinical examination
and that should guide the laboratory analysis and
additional investigations.
Recommendations
• Recommendation 1 strongly advises that the patient
be seen early and examined by a rheumatologist, no later
than 6 weeks after joints symptoms appear.
• Recommendation 2 places clinical examination first,
with the condition of confirmation by ultrasonography.
• Recommendation 3 indicates a series of parameters,
as the number of painful and swollen joints, the level of
acute phase reactants, the rheumatoid factor or anticitrullinated protein antibodies titer, and the imaging
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changes, that must be evaluated in patients with
undifferentiated early arthritis.
• Recommendation 4 strongly indicates that treatment
with
disease-modifying
antirheumatic
drugs
(DMARDs) should start no later than 3 months after the
joint symptoms appear, even if patients do not fulfill the
classification criteria for a rheumatologic inflammatory
disease.
• Recommendation 5 highlights that methotrexate
should be used as first line therapy in patients at risk for
persistent disease with no contraindication for MTX.
• Recommendation
6
strongly
recommends
nonsteroidal anti-inflammatory drugs (NSAIDs) as a
therapy that should be used carefully, only for a short
period of time and at the lowest effective dose.
• Recommendation 7 presents the beneficial effects of
corticosteroids on pain, swelling, and structural
progression reduction, but recommend corticosteroids
only as a temporary adjuvant treatment, no longer than
6 months.
• Recommendation 8 advises taking into account the
comorbidities and the side effects of disease-modifying
antirheumatic drugs (DMARDs) in the therapeutic
management of early arthritis.
• Recommendation 9 indicates some variables,
including assessments of the number of swollen and
painful joints, visual analog scale (VAS), C-reactive
protein (CRP) and erythrocyte sedimentation rate
(ESR), be used in monitoring the disease activity, and
that these should be performed between 1 and 3 months
until reaching the therapeutic target.
• Recommendation 10 takes into consideration
rehabilitation exercises and therapies that could be used
as adjuvants for treatment.
• Recommendation 11 highly recommends primary
prevention in patients with early arthritis, including
quitting smoking, dental care, weight control, or
vaccination.
• Recommendation 12 highlight the importance that
different information and education programs could
have on patients in order to help them maintain work
capacity and to cope with the pain and the functional
deficit.
Treatment with nonsteroidal anti-inflammatory
drugs (NSAIDs), if used long term, is a major risk factor
for renal injury, via direct nephrotoxic effects, with
acute tubular necrosis. Kidney injury may lead to
chronic kidney disease, with the necessity of chronic
dialysis (22, 23). The renal function may be affected also
by other mechanisms, such as obstruction of the urinary
tract, which may manifest over time with chronic kidney

disease, usually well tolerated by the patients, due to
slow installation (24, 25). Use of NSAIDs as analgesics
in the postoperative period, for example, may further
deteriorate the renal function (26-28). Treatment with
NSAIDSs should be used with caution in patients with
cardiovascular comorbidities (29, 30).
Disease-modifying antirheumatic drugs (DMARDs)
treatment
The conventional anti-rheumatic drugs (synthetic
disease-modifying/ csDMARDs) have been shown to
diminish disease progression in chronic inflammatory
arthritis, such as RA and psoriatic arthritis (PsA) (31).
Furthermore, biological DMARDs have demonstrated
rapid and sustained disease control associated with a
reduction of joint destruction.
Methotrexate (MTX) is the first line therapy used to
treat early arthralgia, to reverse or limit impending
exacerbation to RA (32). A randomized, placebocontrolled study (2015) was done in patients with no
ACPA/ FR, without clinical arthritis, arthralgia <1 year
(suspected clinical arthralgia), MRI inflammation,
treated with 120 mg methylprednisolone + MTX /
placebo for 12 months (33). Results showed an
important influence of the treatment on the installation
of clinical arthritis (33).
A prospective, placebo-controlled, double-blind
study (2012) in 110 patients with undifferentiated
arthritis using MTX 15 mg/ week, for 1 year showed the
improvement and reduction of the progression of
arthralgia, especially in ACPA positive patients (34).
Corticosteroid treatment. Corticosteroids improve
clinical and radiological outcomes. Therapy with
systemic corticosteroids should be temporary due to the
risk of side effects, including weight gain, hypertension,
diabetes, cataract, and osteoporosis, which justify
careful monitoring and appropriate prevention (35).
Dexamethasone
has demonstrated effect on
autoantibody levels in early arthritis (36). In 2010, in a
case-control study on 83 ACPA positive patients with
arthralgia, without signs of undifferentiated arthritis,
using 2 administrations of Dexamethasone 100 mg at 6week intervals, the results showed ACPA and FR
titration reduction, but no delay in the progression of the
disease to clinically non-differentiated arthritis (37).
Antimalarial treatment. Although the current data
could not show an important
effect of
hydroxychloroquine (HCQ) in early arthritis or RA, as
it has in systemic lupus erythematosus (SLE), some
studies have established its possible use in specific
patients.
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Hydroxychloroquine. It seems that the antimalarial
therapy can be used in case of arthritis progressing to
RA or other connective tissue diseases in patients with
palindromic rheumatism. In a retrospective study on 113
patients diagnosed with palindromic rheumatism and 33
with RA, this therapy reduced progression to RA in 69%
of patients treated with HCQ (38, 39).
Biological treatment. This kind of treatment opened
a new era in the management of many inflammatory
diseases. In early arthritis and RA, it is used as a second
line therapy in patients with severe disease who do not
respond or who have a contraindication to DMARDs,
the first line of therapy still remaining the methotrexate.
Rituximab. The PRAIRI study (2016) showed the
prevention of RA by B cell-directed therapy in the
earliest phase of the disease. In this randomized,
placebo-controlled, double-blind study, on 81 patients
during 29 months, without clinically obvious arthritis,
with rheumatoid factor, ACPA positive, elevated levels
of C-reactive protein, subclinical US/ MRI synovitis,
with 40 patients using 1000 mg rituximab/ 40 placebo
(premedication with 100 mg methylprednisolone),
results showed that patients using rituximab developed
RA at 24 months vs 12 months with placebo (40).
Infliximab did not demonstrate surprising results. In
a double-blind, placebo-controlled study on 17 patients
with undifferentiated arthritis <12 months (10 using
infliximab, 7 placebo), this treatment showed a Creactive protein reduction after 14 weeks, with HAQ
(Health Assessment Questionnaire) improvement (40).
In the 26th week: no statistical significance DAS 28
(Disease Activity Score), with only a small reduction in
morning stiffness. In week 52, all patients (Interferon
users+ placebo) had developed RA.
Abatacept. Studies using this biological treatment
are yet in progress. The APPIPRA study aims to show
the reverse of subclinical inflammation. Begun in
December 2017 and estimated to finish in December
2018, this study uses a randomized, placebo-controlled
design on anti-citrullinated protein antibodies (ACPA)
positive patients with joint pain, without clinically
obvious arthritis, comparing 125 mg Abatacept vs
placebo (41, 42).

Conclusions
Patients with early arthritis should be referred to the
rheumatologist in order to recognize the presence of
arthritis and to confirm the potential diagnosis. Prompt
initiation of treatment is essential. The management of
early arthritis should include drug treatment associated
with medical education (43). Comorbidities in patients

with early arthritis play an important role for the
therapeutical decision (44-46). The shared decision
between patient and rheumatologist plays an important
role for allied healthcare professionals.
Though no cure for rheumatoid arthritis is available,
patients can take positive steps to delay some of the
more severe joints damage and allow them to continue
to live a long, healthy life.
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